PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

EULAR launches the EULAR Network of Trial Centres (ENTRI), a unique initiative transforming the way clinical trials are delivered

Stop searching, start researching! Your RMD clinical trials journey starts here

2024-06-14
(Press-News.org) ENTRI aims to: 

Create a network of clinical trial centres, accessible to all investigators and sponsors from both public and private sectors. Build capacity and training in clinical trials and experimental medicine studies. Provide RMD-related clinical trials toolkits underpinned by best practice.  

By facilitating the delivery of incisive research trial studies, ENTRI helps generate the evidence required to implement changes in clinical practice that are meaningful and beneficial to patients. ENTRI members will be invited to participate in cutting-edge projects sponsored by both public and private sectors. Facilitating faster translation of results into clinical practice requires active engagement and participation from practising clinicians and investigators. ENTRI will help establish platforms for prosecuting scientifically rigorous trials, addressing the most pressing clinical needs, engaging and reaching out to eligible patients in a faster and more efficient way. By applying a portfolio of carefully designed operating procedures, ENTRI will therefore help streamline efforts of investigators and sponsors to deliver trials in a timely manner, optimising administrative processes, and reducing costs.

 

Through training programmes, ENTRI also aims to support investigators to develop and build research capacity and clinical trial skill sets. Within a few years, EULAR hopes to provide investigators with programmes tailored to their needs, focusing on good clinical practice and related skills for investigators across the full spectrum of expertise.

 

The EULAR Research Centre will oversee a two-step application process, starting with an Expression of Interest (EoI). This will be followed by an invitation to complete a full application, which aims to capture in more detail the resources and experience of each Centre.

 

EULAR invites EoI from any organisation or institution:

Promoting excellence in patient care.   Demonstrating commitment to clinical research.  With oversight into capacity and capabilities in clinical trials and experimental medicine studies and/or  Experience in sponsoring clinical research (desirable, but not essential). Demonstrating expertise, or a clear willingness to further develop the skills in recruiting patients with RMDs to research studies.  

About EULAR

EULAR is the European umbrella organisation representing scientific societies, health professional associations and organisations for people with RMDs. EULAR aims to reduce the impact of RMDs on individuals and society, as well as improve RMD treatments, prevention, and rehabilitation. To this end, EULAR fosters excellence in rheumatology education and research, promotes the translation of research advances into daily care, and advocates for the recognition of the needs of those living with RMDs by EU institutions.

 

Contact

EULAR ENTRI team, entri@eular.org

EULAR Communications, communications@eular.org

 

Notes to Editors

EULAR Recommendations

EULAR School of Rheumatology

EULAR Press Releases

 

END


ELSE PRESS RELEASES FROM THIS DATE:

Could interferon signature aid in the diagnosis and stratification of pediatric Sjögren’s?

2024-06-14
Sjögren’s disease is rare in children, and presenting symptoms differ from those seen in adults. For example, paediatric patients present less often with sicca complaints, and more frequently with parotid gland swelling and fever.1 This new work aimed to identify potentially dysregulated molecular pathways in children with Sjögren’s disease by comparing the transcriptome of peripheral blood cells between 18 patients and 23 controls – using differential gene expression and pathway analysis. In addition to whole transcriptome analysis of blood samples, expression of interferon-stimulated genes (ISG) was measured in paired ...

Putting rheumatic and musculoskeletal diseases (RMDs) at the forefront of the next European Union healthcare agenda

2024-06-14
Why are RMDs an issue for Europe? RMDs, often dubbed 'the invisible diseases', affect approximately 120 million Europeans, constituting one in five individuals across the continent. Despite their prevalence, there remains a significant lack of awareness among policymakers and the general public, leading to their frequent neglect in political and financial agendas. However, the impact of RMDs is far-reaching, contributing to physical disability, chronic health conditions, and substantial economic burdens, amounting to an estimated 240 billion Euros annually. Furthermore, RMDs not only pose a direct threat to individual health but also contribute to the ...

Tackling issues in childhood arthritis

2024-06-14
Community awareness that children and young people get arthritis is low.1 This is associated with delays in diagnosis, worse clinical outcomes, and adverse societal factors such as stigma and isolation. Raising awareness of childhood arthritis is crucial in combatting these issues to improve the lives of those living with JIA. An abstract plenary session at the 2024 EULAR congress shared work from Juvenile Arthritis Research – a patient organisation in the UK that is involved in a variety of projects to raise awareness and support JIA patients and their families. These include a variety ...

Predictors for organ damage

2024-06-14
cSLE is a rare multisystem disorder with significant associated morbidity, but evidence-based guidelines are sparse, and as such management is often based on clinical expertise.2 The EULAR/ACR-2019 criteria have shown sensitivity in cSLE patients, which could allow earlier recognition of patients with single or major organ involvement,3 but identifying specific predictors in this vulnerable group is vital for preventing long-lasting damage.   The new work, presented at the 2024 EULAR congress, aimed ...

Osteoarthritis: associations and comorbidities

2024-06-14
In the 2023 update of their recommendations for osteoarthritis management, EULAR – The European Alliance of Associations for Rheumatology – recognise osteoarthritis as a severe disease, and one with important implications for both the individual and society.3 However, most people with osteoarthritis do not receive optimal management,4,5 and this represents an important unmet need – especially when considering additional systemic comorbidities. To explore this further, ComOA6 has combined case-control and cohort studies for over 3 million people in primary care in the UK, Netherlands, Sweden, and Spain. The analyses – shared at ...

High-precision measurements challenge our understanding of Cepheids

High-precision measurements challenge our understanding of Cepheids
2024-06-14
“Classical Cepheids” are a type of pulsating star that rhythmically brightens and dims over time. These pulsations help astronomers measure vast distances across space, which makes Cepheids crucial “standard candles” that help us understand the size and scale of our universe. Despite their importance, studying Cepheids is challenging. Their pulsations and potential interactions with companion stars create complex patterns that are difficult to measure accurately. Different instruments and methods used over the years have led to inconsistent data, ...

New approach to identifying altermagnetic materials

New approach to identifying altermagnetic materials
2024-06-14
Magnetic materials have traditionally been classified as either ferromagnetic, like the decorative magnets on iron refrigerator doors that are seemingly always magnetic, or antiferromagnetic, like two bar magnets placed end-to-end with opposite poles facing each other, canceling each other out so that the material has no net magnetism. However, there appears to be a third class of magnetic materials exhibiting what in 2022 was dubbed altermagnetism. Microscopically, magnetism arises from a collection of tiny magnets associated with electrons, ...

Is magnesium the sleeping potion that enables sandhoppers to survive cold winters?

Is magnesium the sleeping potion that enables sandhoppers to survive cold winters?
2024-06-14
Magnesium compounds are a common ingredient of many remedies designed to help people wind down and escape the stresses of modern life. However, a new study has shown it is not only humans that are using forms of the chemical as a way to help them survive challenging conditions. In tests conducted on beaches in Cornwall, and in the laboratory at the University of Plymouth, scientists confirmed the findings of previous studies which showed large sandhoppers (Talitrus saltator) increase the levels of magnesium ions in their bodies as temperatures fall. This slows them down so they are less active than they would be during the warmer months. However, the new study has shown for the first time ...

Report highlights trajectory challenges for women in elite football

2024-06-14
Report highlights trajectory challenges for women in elite football       A new report commissioned by the Fédération Internationale de Football Association (FIFA) and Fédération Internationale des Associations de Footballeurs Professionnels (FIFPRO), undertaken by Edith Cowan University (ECU), surveyed footballers across 12 countries in six confederations. More than 700 players participated in the survey, with 71.5% classifying themselves as professional, with a further ...

How men can better support each other’s mental health

How men can better support each other’s mental health
2024-06-14
Men are often urged to talk about their mental health with friends, but what does that involve? This week, researchers from the Men’s Health Research Program at UBC introduced In Good Company, a website and podcast series aimed at answering precisely that question. The website provides practical advice for men seeking to make new connections, strengthen existing relationships and provide mutual support. The podcast series interviews men’s health experts and psychologists to explore the nuances and benefits of authentic male connection. Both ...

LAST 30 PRESS RELEASES:

Two frontiers: Illinois experts combine forces to develop novel nanopore sensing platform

Biotechnology governance entreaties released, echoing legacy of 1975 recombinant DNA guidelines

Review of active distribution network reconfiguration: Past progress and future directions

Revealing the lives of planet-forming disks

What’s really in our food? A global look at food composition databases and the gaps we need to fix

Racial differences in tumor collagen structure may impact cancer prognosis

Museomics highlights the importance of scientific museum collections

Fossil corals point to possibly steeper sea level rise under a warming world

The quantum mechanics of chiral spin selectivity

Bodybuilding in ancient times: How the sea anemone got its back

Science and innovation for a sustainable future

Strange radio pulses detected coming from ice in Antarctica

Amazon trees under pressure: New study reveals how forest giants handle light and heat

Cell-depleting treatment in severe RMD: New data

Vasodilation in systemic sclerosis

New ideas in gout management

Risk factors for progression in spondyloarthritis

Patient experiences In JIA

Patient organizations: The partner by your side

Nurses: A critical role for people with RMD

Online information for patients needs guidance

The many ways that AI enters rheumatology

Pregnancy outcomes in autoinflammatory disease

The value of physical activity for people with RMD

First data from the EULAR RheumaFacts project

Research spotlight: Preventing stalling to improve CAR-T cells’ efficacy against tumors

c-Fos expression differentially acts in the healthy brain compared with Alzheimer’s disease

Computed tomography perfusion and angiography for death by neurologic criteria

New tool could help Florida homeowners weather flood risks, lower insurance costs

Researchers develop a rapid method for building vascular organoids

[Press-News.org] EULAR launches the EULAR Network of Trial Centres (ENTRI), a unique initiative transforming the way clinical trials are delivered
Stop searching, start researching! Your RMD clinical trials journey starts here